Benzo[f]indole-4,9-dione Derivatives Effectively Inhibit the Growth of Triple-Negative Breast Cancer

Area of Science:

• Medicinal Chemistry
• Oncology
• Biochemistry

Background:

• Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to a lack of effective targeted therapies.
• Indole derivatives have demonstrated potential antitumor properties against various cancer types.
• Developing novel therapeutic agents for TNBC is a critical unmet need.

Purpose of the Study:

• To investigate the potential of novel benzo[f]indole-4,9-dione derivatives as therapeutic agents against TNBC.
• To elucidate the mechanism of action of these compounds in TNBC cells.

Main Methods:

• Synthesis and characterization of four new benzo[f]indole-4,9-dione derivatives.
• In vitro assessment of compound efficacy on TNBC cell viability (MDA-MB 231 cell line).
• Analysis of apoptosis induction, reactive oxygen species (ROS) generation, and caspase activation pathways.

Main Results:

• The four benzo[f]indole-4,9-dione derivatives significantly reduced TNBC cell viability in vitro.
• Compounds induced cell death through the accumulation of reactive oxygen species (ROS).
• Cytotoxic effects were mediated by the intrinsic apoptosis pathway, involving caspase 9 and the Bax/Bcl-2 ratio.

Conclusions:

• The novel benzo[f]indole-4,9-dione derivatives exhibit potent anti-TNBC activity.
• These compounds represent potential therapeutic candidates for TNBC treatment by inducing ROS-mediated apoptosis.
• Targeting the intrinsic apoptosis pathway via caspase activation is a viable strategy for TNBC therapy.